Literature DB >> 19951173

IFN-beta-induced alteration of VSV protein phosphorylation in neuronal cells.

Paul M D'agostino1, Jessica J Amenta, Carol Shoshkes Reiss.   

Abstract

Vesicular stomatitis virus (VSV) replication is highly sensitive to interferon (IFN)-induced antiviral responses. VSV infection of well-known cell lines pretreated with IFN-beta results in a 10(4)-fold reduction in the release of infectious particles, with a concomitant abrogation in viral transcript and/or protein levels. However, in cell lines of neuronal lineage only a threefold reduction in viral transcript and protein levels was observed, despite the same 10(4)-fold reduction in released infectious virions, suggesting an assembly defect. Examination of VSV matrix (M) protein ubiquitination yielded no differences between mock- and IFN-beta-treated neuronal cells. Further analysis of potential post-translational modification events, by scintillation and two-dimensional electrophoretic methods, revealed IFN-beta-induced alterations in M protein and phosphoprotein (P) phosphorylation. Hypophosphorylated P protein was demonstrated by reduced (32)P counts, normalized by (35)S-cysteine/methionine incorporation, and by a shift in isoelectric focusing. Hypophosphorylation of VSV P protein was found to occur in neuronal cell lysates, but not within budded virions from the same IFN-beta-treated cells. In contrast, hyperphosphorylation of VSV M protein was observed in both cell lysates and viral particles from IFN-beta-treated neuronal cells. Hyperphosphorylated M protein was demonstrated by increased (32)P counts relative to (35)S-cysteine/methionine normalization, and by altered isoelectric focusing in protein populations from cell and viral lysates. Hyperphosphorylated VSV M protein was found to inhibit its association with VSV nucleocapsid, suggesting a possible mechanism for type I IFN-mediated misassembly through disruption of the interactions between ribonucleoprotein cores, and hyperphosphorylated M protein bound to the plasma membrane inner leaflet.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19951173      PMCID: PMC2812813          DOI: 10.1089/vim.2009.0057

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  57 in total

1.  Both NS and L proteins are required for in vitro RNA synthesis by vesicular stomatitis virus.

Authors:  S U Emerson; Y Yu
Journal:  J Virol       Date:  1975-06       Impact factor: 5.103

2.  Requirements and functions of vesicular stomatitis virus L and NS proteins in the transcription process in vitro.

Authors:  B P De; A K Banerjee
Journal:  Biochem Biophys Res Commun       Date:  1985-01-16       Impact factor: 3.575

3.  Mapping regions of the matrix protein of vesicular stomatitis virus which bind to ribonucleocapsids, liposomes, and monoclonal antibodies.

Authors:  J R Ogden; R Pal; R R Wagner
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

4.  The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. II. Monoclonal antibodies of nonneutralizing and cross-reactive epitopes of Indiana and New Jersey serotypes.

Authors:  L Lefrancois; D S Lyles
Journal:  Virology       Date:  1982-08       Impact factor: 3.616

5.  Cell and virus sensitivity studies with recombinant human alpha interferons.

Authors:  M J Kramer; R Dennin; C Kramer; G Jones; E Connell; N Rolon; A Gruarin; R Kale; P W Trown
Journal:  J Interferon Res       Date:  1983

6.  Specific interactions of vesicular stomatitis virus L and NS proteins with heterologous genome ribonucleoprotein template lead to mRNA synthesis in vitro.

Authors:  B P De; A K Banerjee
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

7.  Interferon-induced ISG15 conjugation inhibits influenza A virus gene expression and replication in human cells.

Authors:  Tien-Ying Hsiang; Chen Zhao; Robert M Krug
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

8.  Interferon-treated cells release vesicular stomatitis virus particles lacking glycoprotein spikes: correlation with biochemical data.

Authors:  R K Maheshwari; A E Demsey; S B Mohanty; R M Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

9.  The effect of interferon on de novo infection of Moloney murine leukemia virus.

Authors:  P K Wong; P H Yuen; R MacLeod; E H Chang; M W Myers; R M Friedman
Journal:  Cell       Date:  1977-02       Impact factor: 41.582

10.  Identity of HeLa cell determinants acquired by vesicular stomatitis virus with a tumor antigen.

Authors:  L M Little; J Zavada; C J Der; A S Huang
Journal:  Science       Date:  1983-06-03       Impact factor: 47.728

View more
  7 in total

1.  A confocal and electron microscopic comparison of interferon beta-induced changes in vesicular stomatitis virus infection of neuroblastoma and nonneuronal cells.

Authors:  Paul M D'Agostino; Carol Shoshkes Reiss
Journal:  DNA Cell Biol       Date:  2010-03       Impact factor: 3.311

2.  DISTINCT MECHANISMS OF INHIBITION OF VSV REPLICATION IN NEURONS MEDIATED BY TYPE I AND TYPE II IFN.

Authors:  Paul M D'Agostino; Jingjun Yang; Carol Shoshkes Reiss
Journal:  Virus Rev Res       Date:  2009-01-01

3.  Interferon-induced tetherin restricts vesicular stomatitis virus release in neurons.

Authors:  Sreeja Sarojini; Thana Theofanis; Carol Shoshkes Reiss
Journal:  DNA Cell Biol       Date:  2011-09-15       Impact factor: 3.311

4.  The type I interferon response bridles rabies virus infection and reduces pathogenicity.

Authors:  Damien Chopy; Claudia N Detje; Mireille Lafage; Ulrich Kalinke; Monique Lafon
Journal:  J Neurovirol       Date:  2011-07-30       Impact factor: 2.643

5.  M51R and Delta-M51 matrix protein of the vesicular stomatitis virus induce apoptosis in colorectal cancer cells.

Authors:  Zahra Gray; Alijan Tabarraei; Abdolvahab Moradi; Mohamad R Kalani
Journal:  Mol Biol Rep       Date:  2019-04-20       Impact factor: 2.316

Review 6.  Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.

Authors:  Markus Moehler; Katrin Goepfert; Bernd Heinrich; Caroline J Breitbach; Maike Delic; Peter Robert Galle; Jean Rommelaere
Journal:  Front Oncol       Date:  2014-05-01       Impact factor: 6.244

Review 7.  Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.

Authors:  Suman Bishnoi; Ritudhwaj Tiwari; Sharad Gupta; Siddappa N Byrareddy; Debasis Nayak
Journal:  Viruses       Date:  2018-02-23       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.